Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 1/20 | 0.44 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.44 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.43 |
| ▸ | NCF1 | P14598 | 1/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.37 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 2/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29564829 | 0.98 | AXL (0.42) | AXLMKNK1MKNK2ADORA2AADORA1 | |
| Hydrochloric Acid SCHEMBL6196269 | 0.98 | AXL (0.42) | AXLMKNK1MKNK2ADORA2AADORA1 | |
| Formic Acid SCHEMBL29564870 | 0.89 | PDPK1 (0.39) | AXLMKNK1MKNK2ADORA2AADORA1 | |
| Trifluoroacetic Acid SCHEMBL31744994 | 0.83 | ADORA2A (0.42) | ADORA2AADORA1HSD17B10KDRADORA2B | |
| SCHEMBL31324910 | 0.74 | AXL (0.44) | AXLMKNK1MKNK2ADORA2AADORA1 | |
| SCHEMBL29631094 | 0.74 | AXL (0.44) | AXLMKNK1MKNK2ADORA2AADORA1 | |
| SCHEMBL21393430 | 0.74 | AXL (0.44) | AXLMKNK1MKNK2ADORA2AADORA1 | |
| SCHEMBL29365402 | 0.74 | AXL (0.53) | AXLMKNK1MKNK2ADORA2AADORA1 | |
| SCHEMBL29368189 | 0.74 | AXL (0.44) | AXLMKNK1MKNK2ADORA2AADORA1 | |
| SCHEMBL29468124 | 0.74 | AXL (0.44) | AXLMKNK1MKNK2ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400591-A1 | COMPOUNDS TARGETING MUTANT OF P53 | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-12-05 | — | — | US | claimed |
| EP-4398987-A1 | METHODS FOR TREATING NEUROGENERATIVE DISEASES | PTC Therapeutics, Inc. (US) | 2024-07-17 | — | — | EP | claimed |
| WO-2023039369-A1 | METHODS FOR TREATING NEUROGENERATIVE DISEASES | PTC THERAPEUTICS, INC. (US) | 2023-03-16 | — | — | WO | claimed |
| WO-2022058896-A1 | INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE FOR MANAGEMENT OF METABOLIC DISORDER | CADILA HEALTHCARE LIMITED (IN) | 2022-03-24 | — | — | WO | claimed |
| EP-1537123-B1 | AMINO-SUBSTITUTED CYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS | GLAXO GROUP LTD (GB) | 2009-04-29 | — | — | EP | claimed |
| US-20260098044-A1 | TRICYCLIC HETEROARYL COMPOUNDS AS INHIBITORS OF TYK2 AND/OR JAK1 | INCYTE CORP (US) | 2026-04-09 | — | — | US | disclosed |
| US-20250382305-A1 | COMPOUNDS FOR TREATING SPINOCEREBELLAR ATAXIA TYPE 3 | PTC THERAPEUTICS INC (US) | 2025-12-18 | — | — | US | disclosed |
| US-12384797-B2 | Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia | PTC THERAPEUTICS, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| US-20240400591-A1 | COMPOUNDS TARGETING MUTANT OF P53 | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-12-05 | — | — | US | disclosed |
| US-20240390338-A1 | METHODS FOR TREATING NEUROGENERATIVE DISEASES | PTC THERAPEUTICS, INC. | 2024-11-28 | — | — | US | disclosed |
| US-20240150293-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | VERNALIS (R&D) LTD (GB) | 2024-05-09 | — | — | US | disclosed |
| US-20240051968-A1 | METHODS FOR TREATING SPINOCEREBELLAR ATAXIA TYPE 3 | PTC THERAPEUTICS, INC. (US) | 2024-02-15 | — | — | US | disclosed |
| EP-2804859-B1 | NOVEL FAP INHIBITORS | UNIV ANTWERPEN (BE) | 2019-06-12 | — | — | EP | disclosed |
| WO-2018136634-A1 | FUSED HETEROCYCLIC COMPOUNDS AS SELECTIVE BMP INHIBITORS | VANDERBILT UNIVERSITY (US) | 2018-07-26 | — | — | WO | disclosed |
| US-20170145009-A1 | HETEROCYCLIC COMPOUNDS THAT INHIBIT THE KINASE ACTIVITY OF MNK USEFUL FOR TREATING VARIOUS CANCERS | EFFECTOR THERAPEUTICS, INC. | 2017-05-25 | — | — | US | disclosed |
| CN-101796055-B | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC | 2013-09-04 | — | — | CN | disclosed |
| CN-101248080-B | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC | 2012-09-05 | — | — | CN | disclosed |
| CN-101796055-A | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC | 2010-08-04 | — | — | CN | disclosed |
| CN-101248080-A | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC (CA) | 2008-08-20 | — | — | CN | disclosed |
| US-4935431-A | Substituted 7-amino-thienopyridine derivatives as gastric acid secretion inhibitors | SMITHKLINE BECKMAN INTERCREDIT B.V. (NL) | 1990-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150293-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | BCL2, BAX, BCL2A1 | AXL 4248/4885MKNK1 1823/4885MKNK2 1703/4885 |
| US-20250382305-A1 | COMPOUNDS FOR TREATING SPINOCEREBELLAR ATAXIA TYPE 3 | ATXN2, SMN1; SMN2, ATXN10 | AXL 4834/4885MKNK1 2141/4885MKNK2 2008/4885 |
| US-20240051968-A1 | METHODS FOR TREATING SPINOCEREBELLAR ATAXIA TYPE 3 | ATXN2, ATXN10, ATXN2L | AXL 4646/4885MKNK1 4038/4885MKNK2 3519/4885 |
| US-20240400591-A1 | COMPOUNDS TARGETING MUTANT OF P53 | TP53, TP53BP1, MDM2 | AXL 4611/4885MKNK1 673/4885MKNK2 628/4885 |
| US-12384797-B2 | Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia | SF3B5, SF3B2, SF3B1 | AXL 4439/4885MKNK1 3544/4885MKNK2 2295/4885 |
| US-20240390338-A1 | METHODS FOR TREATING NEUROGENERATIVE DISEASES | MAPT, MAP1B, MAP2 | AXL 4671/4885MKNK1 884/4885MKNK2 704/4885 |
| US-20170145009-A1 | HETEROCYCLIC COMPOUNDS THAT INHIBIT THE KINASE ACTIVITY OF MNK USEFUL FOR TREATING VARIOUS CANCERS | MAP3K9, MAP3K19, MAP3K20 | AXL 776/4885MKNK1 78/4885MKNK2 62/4885 |
| US-20260098044-A1 | TRICYCLIC HETEROARYL COMPOUNDS AS INHIBITORS OF TYK2 AND/OR JAK1 | JAK1, TYK2, JAK2 | AXL 1200/4885MKNK1 1096/4885MKNK2 1138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.